Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H6F2N4O |
| Molecular Weight | 284.2204 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CN=C(C=C1)C2=NOC(=N2)C3=CC(=CC(F)=C3)C#N
InChI
InChIKey=RBSPCALDSNXWEP-UHFFFAOYSA-N
InChI=1S/C14H6F2N4O/c15-10-1-2-12(18-7-10)13-19-14(21-20-13)9-3-8(6-17)4-11(16)5-9/h1-5,7H
| Molecular Formula | C14H6F2N4O |
| Molecular Weight | 284.2204 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
AZD-9272 is an orally bioavailable and brain-penetrant potent and selective mGluR5 negative allosteric modulator. It exhibits high selectivity for mGluR5 over other mGlu receptors. It had been in phase I clinical trials for the treatment of gastroesophageal reflux disease and neuropathic pain. Single doses of the centrally acting mGluR5-antagonist AZD-9272 did not reduce C-fibre evoked pain, central sensitization or flare reaction in the study aimed to investigate its effect on electrically induced pain, central sensitization and axon reflex flare.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. | 2014-08 |
|
| Evaluation of the effects of a metabotropic glutamate receptor 5-antagonist on electrically induced pain and central sensitization in healthy human volunteers. | 2013-11 |
|
| Palladium mediated ¹¹C-cyanation and characterization in the non-human primate brain of the novel mGluR5 radioligand [¹¹C]AZD9272. | 2013-05 |
|
| Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. | 2012-11-15 |
|
| Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers. | 2012-07-16 |
Sample Use Guides
3-24 mg single dose (the maximum tolerated dose is 24 mg)
Route of Administration:
Oral
[3H]AZD9272 binding in rat striatum was of high affinity and finite capacity (Kd = 9.4 ± 1.9 nM; Bmax = 1553 ± 474 fmol/mg T.E.; ±SD, n = 5) and could be inhibited by MPEP, MTEP and AZD6538 (IC50 AZD6538, 14.5 ± 4.7 nM; MTEP, 24 ± 6.1; n = 2, confirming that these compounds bind to a common site also at the native mGluR5 in rat brain sections.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:26:00 GMT 2025
by
admin
on
Mon Mar 31 18:26:00 GMT 2025
|
| Record UNII |
54SQ9B412I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
54SQ9B412I
Created by
admin on Mon Mar 31 18:26:00 GMT 2025 , Edited by admin on Mon Mar 31 18:26:00 GMT 2025
|
PRIMARY | |||
|
9838729
Created by
admin on Mon Mar 31 18:26:00 GMT 2025 , Edited by admin on Mon Mar 31 18:26:00 GMT 2025
|
PRIMARY | |||
|
300000041406
Created by
admin on Mon Mar 31 18:26:00 GMT 2025 , Edited by admin on Mon Mar 31 18:26:00 GMT 2025
|
PRIMARY | |||
|
327056-26-8
Created by
admin on Mon Mar 31 18:26:00 GMT 2025 , Edited by admin on Mon Mar 31 18:26:00 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
ANTAGONIST
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
